Detail Information of Xenobiotics

General Information of Xenobiotics (ID: XEO00142)
Xenobiotics Name
Voriconazole
Xenobiotics Type
Pharmaceutical Agent(s)
Classification
Approved/Marketed Drug
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=71616"></iframe>
3D MOL 2D MOL
PubChem CID
71616
DME(s) Modulated by This Xenobiotics
DME(s) Inhibited by This Xenobiotics
Mephenytoin 4-hydroxylase (CYP2C19) DME Info Homo sapiens [1], [2]
Cytochrome P450 2C9 (CYP2C9) DME Info Homo sapiens [1], [2]
Cytochrome P450 3A4 (CYP3A4) DME Info Homo sapiens [3]
Xenobiotics-DME Activity Data
Xenobiotics-DME Activity Data Mephenytoin 4-hydroxylase (CYP2C19) DME Info IC50 = 15 microM [1], [2]
Cytochrome P450 2C9 (CYP2C9) DME Info IC50 = 14 microM [1], [2]
Cytochrome P450 3A4 (CYP3A4) DME Info IC50 = 13 microM [3]
References
1 Breakthrough Candida infections in patients receiving voriconazole. Ann Pharmacother. 2005 Jul-Aug;39(7-8):1342-5.
2 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
3 Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3455-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.